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cular complications- 41%. In the type 1 diabetes group the cost was equal to 15 364 
EUR with the following split: 63% due to (general) diabetes, 19% due to microvascular 
complications, and 18% due to macrovascular complications. ConClusions: Type 
2 diabetes is more costly than type 1 when hospitalizations occur. People with type 
2 diabetes pay high cost for macrovascular complications than for microvascular 
probably due to high hypertension prevalence. The difference in costs between type 
1 and 2 may result from different patients’ characteristics.
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objeCtives: Due to the preparation for the transition to health insurance in Ukraine 
and because of the significant increase in thyroid disease it is important to assess a 
range of medicines included to the Ukrainian National Formulary (UNF). Methods: It 
was compared the range of drugs for treatment of thyroid disease which are included 
to the Ukrainian National Formulary with the WHO Model list of Essential Medicines. 
Also it was calculated the annual cost of treatment by each medication considering 
the usual maintenance dose. Results: In accordance to WHO Model List of Essential 
Medicines it was established that Ukrainian National Formulary includes thyroid 
hormones and antithyroid medicines for thyroid disease treatment such as: levothy-
roxine sodium and potassium iodide. Also it was found that there are no propylthi-
ouracil medications in UNF. The dosage of levothyroxine sodium tablets satisfies the 
norms of World Health Organization, which are: 25 micrograms, 50 micrograms and 
100 micrograms. Potassium iodide tablets in dose of 100 micrograms, 200 micrograms, 
1 mg does not comply the norm. According to WHO Model list of Essential Medicines 
dosage of potassium iodide in tablets should be 60 mg. The cheapest annual cost of 
treatment by levothyroxine per patient is EUR 10,95 (The EUR/UAH conversion rate: 1 
EUR = 10,52 UAH (Average 2013)), the most expensive is EUR 80,30. The most expensive 
annual cost of treatment by potassium iodide per patient is EUR 31,32, the cheapest is 
EUR 2,85. ConClusions: Propylthiouracil should be included to Ukrainian National 
Formulary. The cost difference of thyroid disease treatment by essential medicines 
caused by presence of foreign products in the pharmaceutical market of Ukraine.
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objeCtives: The randomized controlled ABACUS study assessed the impact of 
using the automated insulin bolus advisor within the Accu-Chek Aviva Expert sys-
tem in combination with intensive diabetes therapy on glycemic control in patients 
treated with MDI therapy. This analysis assessed the potential incremental eco-
nomic benefit of using this automated bolus advisor device on the short-term health 
care costs (SHC). Methods: The study outcome parameter was “achieving the goal 
of an at least 0.5% reduction in HbA1c”. The economic analysis was performed with a 
spreadsheet-model from a UK payer’s direct cost perspective and based on ABACUS 
outcomes. Data on correlation between HbA1c change and expected cost are based 
on published literature. Model outputs include expected impact on SHC and sen-
sitivity analysis. Results: A total of 56% of patients in the intervention group (IG) 
achieved the goal, in the control group (CG) 34% respectively. Goal achievement led 
to an average HbA1c reduction of 1.2%, irrespective of group. There was no clinically 
relevant HbA1c effect in the remaining patients. Goal achievement correlates with 
an expected reduction in SHC of £189 per person / per year (PPY). The expected 
SHC reduction is £104 PPY in the IG and £74 PPY in the CG. The goal-achievement-
rate increased by 63%, driving a comparative economic benefit of £30 PPY for an 
automated insulin bolus advisor supported approach. There were no significant dif-
ferences in complications or in intervention cost. ConClusions: An MDI therapy 
in diabetes care that is supported by the Accu-Chek Aviva Expert systems with its 
automated bolus advisor leads to a 63% higher rate of goal achievement. This is 
expected to result in an incremental reduction in short-term health care costs of 
£30 PPY. Hence automated bolus calculation improved the cost-effectiveness of 
self-monitoring of blood glucose in this study population.
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objeCtives: Type 2 diabetes mellitus (DM) is widely spread in Russia, counting 
about 10 million. New drugs are highly effective and carry a high cost for health 
care. The results of clinical trials are not enough to assess long term efficacy 
and safety of treatment. Modeling is a tool for making long term economic and 
outcome prognosis and comparing treatment strategies. The main goal of the pre-
sented study was to develop a predictive model of type 2 DM outcomes validated 
in Russian clinical conditions and to perform pharmacoeconomic evaluation of 
glucose lowering therapies. Methods: Existing type 2 DM models were evalu-
ated. Risk equations for type 2 DM complications were compiled from EAGLE and 
UKPDS DM models. Demographic (age, sex, height, weight, DM duration, smok-
ing), biochemical (HbA1c, lipids) and clinical (blood pressure) patient parameters 
were used as inputs. Glucose lowering drug effectiveness was incorporated into 
$117 associated with HbA1c levls of 6%, 7%, 8% and 9% respectively. ConClusions: 
In insulin treated T2DM subjects lower HbA1c is associated with higher frequency of 
hypoglycaemia and associated costs. Failing to account for the cost burden associ-
ated with hypoglycaemia may underestimate the value of diabetes management 
strategies that minimize hypoglycaemia risk.
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objeCtives: To assess the cost and metabolic outcomes in children with diabetes 
mellitus treated with CSII or with human insulin. Methods: It is a cost-conse-
quence analysis. Retrospectively were observed patients dossier and health care 
resources used during the period 1999 – 2012. The study sample included 34 chil-
dren aged 3 to 18 years with type 1 diabetes. Seventeen of the children are using 
continuous subcutaneous insulin infusion (CSII) therapy and 17 using intensified 
dosage regime of human insulin. The duration of the disease, diabetic control, HbA1c 
deviation scores, height and weight were observed. Cost of pharmacotherapy, test 
strips were calculated and compared with the therapeutic outcomes in both studied 
groups. The average improvement of HbA (1c) after the CSII introduction was chosen 
as therapeutic outcome. Results: Subcutaneous insulin infusion (CSII) systems are 
not a standard treatment for the Bulgarian children; they are of a limited usage and 
are not reimbursed. From the 34 children with diabetes type 1 observed 17 were on 
CSII (mean age 10 years, mean duration of diabetes - 7 years, average usage of CSII - 3 
years). The test stripes costs 533 Euro/ year and their average cost according to the 
duration of the disease is 3779.45 Euro since diagnosis. The blood glucose monitor-
ing system costs 20 Euro and for the duration of the disease - 4.96 Euro per patient 
per year. The CSII price is 3896 Euro and it costs 1292 euro per patient per year. The 
average improvement of HbA (1c) after the CSII introduction is 1.85. In the group 
treated while human insulin the average cost per children is 925 Euro and improve-
ment of HbA (1c) human insulin is 0.28 for the same period. ConClusions: The 
treatment with CSII leads to significant improvement in glycemic control compared 
to the treatment with human insulin at the comparable costs.
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objeCtives: The rising prevalence of overweight and obesity has led to an increase 
in related metabolic disorders; most notably t2dm. We sought to determine how 
the cost of medication for this condition varies within a cohort of patients attend-
ing Galway University Hospital, according to age, gender, BMI and co-morbidity 
status. Methods: We identified a subgroup of 185 adult type 2 diabetes patients 
attending our university hospital-based diabetes clinic, for whom detailed informa-
tion about drug therapy and comorbidities (obesity, hypertension, dyslipidaemia) 
was available. We modelled the lifetime costs of medications for each patient, taking 
account of age, gender and comorbidity. The analysis compares the lifetime cost of 
medication of those patients who are obese relative to those who are overweight 
and of those with fewer to those with more co-morbidities; specifically obesity, 
hypertension and dyslipidaemia. Results: We found that obesity is associated with 
a higher cost of medication relative to being overweight. Those with a BMI range of 
35-39.9 had the highest mean cost of medication, costing on average € 615 more than 
those who are overweight (p< .01). The highest cost of medication was associated 
with those aged 50-65- non-significant. Among those having all three co-morbidities 
compared to those having only t2dm there was a significant difference in the cost 
of medication costing on average an extra € 418 (p< .05). ConClusions: These 
results suggest that the health economic costs associated with t2dm are differential 
with respect to the BMI status of affected individuals. These findings are of use in 
understanding the drug related burden of illness associated with obesity, t2dm and 
also the burden associated with being obese when one has t2dm compared to not 
being obese and having it. This study generated interesting data which will need to 
be replicated in larger prospective multicentre cohort studies.
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objeCtives: It has been shown that people with diabetes have a high prevalence of 
microvascular (neuropathy, nephropathy, retinopathy, diabetic angiopathy) and mac-
rovascular (hypertension, stroke, myocardial infarction, heart failure and coronary 
artery disease) complications leading to hospitalizations. The objective of the present 
study is to evaluate the cost of hospitalizations due to micro- and macrovascular 
complications in an observed cohort of 433 patients with type 1 and 2 diabetes treated 
with insulin. Methods: The evaluation is based on data from a 6 months com-
bined retrospective and prospective observational study. People were separated in two 
groups depending on the type of diabetes and further into subgroups depending on 
the reason of hospitalization. The total costs for each subgroup of people were calcu-
lated and compared to the total costs of treatment for the observed period. Results: 
In the group of people with type 2 diabetes (n= 255) 128 people with complications 
were observed, whereas in people with type 1 diabetes it was only 70 people out of 
178. The cost of hospitalizations in the type 2 diabetes group was in total 35 367 EUR 
for the people enrolled in the 6 months study with the following division of reported 
reasons: (general) diabetes- 43%, microvascular complications- 16%, and macrovas-
